Cargando…

The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma

Intraductal papillomas (IDP) are challenging breast findings because of their variable risk of progression to malignancy. The molecular events driving IDP development and genomic features of malignant progression are poorly understood. In this study, genome-wide CNA and/or targeted mutation analysis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kader, Tanjina, Elder, Kenneth, Zethoven, Magnus, Semple, Timothy, Hill, Prue, Goode, David L., Thio, Niko, Cheasley, Dane, Rowley, Simone M., Byrne, David J., Pang, Jia-Min, Miligy, Islam M., Green, Andrew R., Rakha, Emad A., Fox, Stephen B., Mann, G. Bruce, Campbell, Ian G., Gorringe, Kylie L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067788/ https://www.ncbi.nlm.nih.gov/pubmed/32195332 http://dx.doi.org/10.1038/s41523-020-0150-6

Ejemplares similares

Evaluating statistical approaches to define clonal origin of tumours using bulk DNA sequencing: context is everything
por: Kader, Tanjina, et al.
Publicado: (2022)

Atypical ductal hyperplasia: update on diagnosis, management, and molecular landscape
por: Kader, Tanjina, et al.
Publicado: (2018)

The TP53 mutation rate differs in breast cancers that arise in women with high or low mammographic density
por: Cheasley, Dane, et al.
Publicado: (2020)

The prognostic significance of immune microenvironment in breast ductal carcinoma in situ
por: Toss, Michael S., et al.
Publicado: (2020)

Copy number analysis by low coverage whole genome sequencing using ultra low-input DNA from formalin-fixed paraffin embedded tumor tissue
por: Kader, Tanjina, et al.
Publicado: (2016)

Investigation of monogenic causes of familial breast cancer: data from the BEACCON case-control study
por: Li, Na, et al.
Publicado: (2021)

The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution
por: Miligy, Islam M., et al.
Publicado: (2019)

Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS)
por: Toss, Michael S., et al.
Publicado: (2018)

Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs
por: Li, Na, et al.
Publicado: (2018)

Exome sequencing of familial high-grade serous ovarian carcinoma reveals heterogeneity for rare candidate susceptibility genes
por: Subramanian, Deepak N., et al.
Publicado: (2020)

Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival
por: Takano, Elena A., et al.
Publicado: (2023)

Therapeutic options for mucinous ovarian carcinoma☆
por: Gorringe, Kylie L., et al.
Publicado: (2020)

Molecular comparison of pure ovarian fibroma with serous benign ovarian tumours
por: Hunter, Sally M., et al.
Publicado: (2020)

Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects
por: Li, Na, et al.
Publicado: (2021)

Improving mitotic cell counting accuracy and efficiency using phosphohistone‐H3 (PHH3) antibody counterstained with haematoxylin and eosin as part of breast cancer grading
por: Ibrahim, Asmaa, et al.
Publicado: (2022)

Chemokine (C‐C motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinoma
por: Sonbul, Sultan N, et al.
Publicado: (2017)

Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis
por: Gorringe, Kylie L., et al.
Publicado: (2017)

Loss of heterozygosity: what is it good for?
por: Ryland, Georgina L., et al.
Publicado: (2015)

Lessons from a breast cell annotation competition series for school pupils
por: Lu, Wenqi, et al.
Publicado: (2022)

ATM Regulated PTEN Degradation Is XIAP E3 Ubiquitin Ligase Mediated in p85α Deficient Cancer Cells and Influence Platinum Sensitivity
por: Ali, Reem, et al.
Publicado: (2019)

Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors
por: Ryland, Georgina L., et al.
Publicado: (2015)

Erratum to: Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors
por: Ryland, Georgina L., et al.
Publicado: (2017)

Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2020)

The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ
por: Al-Kawaz, Abdulbaqi, et al.
Publicado: (2021)

The molecular origin and taxonomy of mucinous ovarian carcinoma
por: Cheasley, Dane, et al.
Publicado: (2019)

Phenotypic characterisation of breast cancer: the role of CDC42
por: Chrysanthou, Eleni, et al.
Publicado: (2017)

Amplicon-Dependent CCNE1 Expression Is Critical for Clonogenic Survival after Cisplatin Treatment and Is Correlated with 20q11 Gain in Ovarian Cancer
por: Etemadmoghadam, Dariush, et al.
Publicado: (2010)

Loss of SMAD4 Is Sufficient to Promote Tumorigenesis in a Model of Dysplastic Barrett’s Esophagus
por: Gotovac, Jovana R., et al.
Publicado: (2021)

A rational approach to cancer therapy
por: Gorringe, Kylie L, et al.
Publicado: (2008)

The frequency and clinical significance of DNA polymerase beta (POLβ) expression in breast ductal carcinoma in situ (DCIS)
por: Al-Kawaz, Abdulbaqi, et al.
Publicado: (2021)

BRCA2 carriers with male breast cancer show elevated tumour methylation
por: Deb, Siddhartha, et al.
Publicado: (2017)

Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression
por: Cheasley, Dane, et al.
Publicado: (2022)

The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours
por: El Ansari, Rokaya, et al.
Publicado: (2018)

When Is “Type I” Ovarian Cancer Not “Type I”? Indications of an Out-Dated Dichotomy
por: Salazar, Carolina, et al.
Publicado: (2018)

Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes
por: Hunter, Sally M., et al.
Publicado: (2015)

Targeted therapy for mucinous ovarian carcinoma: evidence from clinical trials
por: Nugawela, Devindee, et al.
Publicado: (2023)

A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk
por: Klimov, Sergey, et al.
Publicado: (2019)

MicroRNA Genes and Their Target 3′-Untranslated Regions Are Infrequently Somatically Mutated in Ovarian Cancers
por: Ryland, Georgina L., et al.
Publicado: (2012)

Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival
por: Joseph, Chitra, et al.
Publicado: (2020)

Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breast
por: Pang, Jia-Min B., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_envpn655f1fgl4fe95uvcjh10t